Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...
With the resolution, compounding pharmacies are no longer able to produce tirzepatide. And the FDA highlighted the point to ...
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...
WW stock popped after announcing a new compounded semaglutide product to benefit from the current shortage of weight loss ...
PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...
The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...
Authorizing Medicare to cover weight loss drugs would increase federal spending by about $35 billion from 2026 to 2034 ...
The group represents makers of compounded versions of drugs that benefit from shortages of branded FDA-approved medications like tirzepatide and Novo's (NVO) rival weight loss therapy, semaglutide.
Eli Lilly And Co. (NYSE:LLY) is ramping up its legal campaign against the compounding companies temporarily allowed to make ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback